Effect of Different Antihypertensive Drugs on Central Blood Pressure

• Status: Active, not recruiting
• Trial end date: 2026-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Trial name) The differential effects of antihypertensive drugs on central blood pressure:

comparison between beta-blocker(BB) and angiotensin receptor blocker ARB)

Objectives) To evaluate the effect of BB, which has vasodilatory effects, on CBP by comparison between ARB, one of the most widely used class of antihypertensives.

Study design) A multicenter, prospective, randomized, controlled, open-label clinical trial for hypertension patients.

Patient enrollment) 110 patients will be enrolled at 2 centers in South Korea.

Patient follow-up) Patients will go through an initial washout period of two weeks prior to randomization. After pre-medication baseline visit and randomization, clinical follow-up will occur at 4, 8, 12 weeks after initial administration of randomized drug. The follow-up visits are office visits.

Primary endpoint) Reduction in CBP at 12 weeks.

Secondary endpoints) Clinical events including adverse reactions to the drugs.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea University Anam Hospital
• Treatments: Nebivolol

Criteria

Inclusion Criteria:

1. For patients with newly diagnosed hypertension: SBP ≥140mmHg or DBP ≥90 mmHg

2. For patients with prior diagnosis of hypertension: SBP ≥140mmHg or DBP ≥90 mmHg after a two-week washout period of previous antihypertensive medications.

3. Patients who wrote the informed consent: The subject should be able to receive informations of treatment, risks, effects and other therapeutic modalities regarding different antihypertensive agents at least verbally, and investigators should be provided written informed consent from a subject or a legally recognized representative prior to giving any treatment related to the study.

Exclusion Criteria:

1. Patients with contraindications or hypersensitive/allergic reactions to any class of antihypertensive agents.

2. Severe hypertension patients: SBP ≥200mmHg or DBP ≥110 mmHg at any visit during the study.

3. Chronic kidney disease (creatinine >1.5mg/dL)

4. Chronic obstructive pulmonary disease

5. Chronic heart failrue (LVEF ≤35%)

6. Patients who are pregnant or plan on becoming pregnant during the duration of the study, both male and female sex

7. Patients who are illiterate, have psychiatric illnesses or who do not agree to be enrolled in the study.

8. Other patients who are deemed unfit for the study as assessed by the investigators.